PCR Stock Overview
Designs, produces, and sells chemical products in Poland and internationally.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 2/6 |
Past Performance | 2/6 |
Financial Health | 6/6 |
Dividends | 3/6 |
PCC Rokita SA Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | zł85.70 |
52 Week High | zł109.80 |
52 Week Low | zł81.10 |
Beta | 1.24 |
11 Month Change | -5.30% |
3 Month Change | -6.34% |
1 Year Change | -3.05% |
33 Year Change | 7.66% |
5 Year Change | 73.13% |
Change since IPO | 158.44% |
Recent News & Updates
Recent updates
Is There An Opportunity With PCC Rokita SA's (WSE:PCR) 36% Undervaluation?
May 30Is PCC Rokita (WSE:PCR) Using Too Much Debt?
Aug 24PCC Rokita's (WSE:PCR) Shareholders Will Receive A Bigger Dividend Than Last Year
Apr 29Is PCC Rokita (WSE:PCR) A Risky Investment?
Jan 18PCC Rokita (WSE:PCR) Is Increasing Its Dividend To zł13.23
Apr 16Why We Like The Returns At PCC Rokita (WSE:PCR)
Mar 19What Is PCC Rokita SA's (WSE:PCR) Share Price Doing?
Jan 25We Like These Underlying Return On Capital Trends At PCC Rokita (WSE:PCR)
Sep 01Why PCC Rokita SA (WSE:PCR) Could Be Worth Watching
Jun 14Are PCC Rokita SA (WSE:PCR) Investors Paying Above The Intrinsic Value?
May 18Returns On Capital At PCC Rokita (WSE:PCR) Have Hit The Brakes
Apr 13Why PCC Rokita's (WSE:PCR) Earnings Are Better Than They Seem
Mar 23PCC Rokita SA's (WSE:PCR) Has Been On A Rise But Financial Prospects Look Weak: Is The Stock Overpriced?
Mar 09Looking For Steady Income For Your Dividend Portfolio? Is PCC Rokita SA (WSE:PCR) A Good Fit?
Feb 19What Does PCC Rokita SA's (WSE:PCR) Share Price Indicate?
Feb 04Is PCC Rokita (WSE:PCR) Using Too Much Debt?
Jan 15Should We Be Excited About The Trends Of Returns At PCC Rokita (WSE:PCR)?
Dec 30Reflecting on PCC Rokita's (WSE:PCR) Share Price Returns Over The Last Three Years
Dec 17PCC Rokita SA's (WSE:PCR) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?
Dec 03Are Dividend Investors Getting More Than They Bargained For With PCC Rokita SA's (WSE:PCR) Dividend?
Nov 20Shareholder Returns
PCR | PL Chemicals | PL Market | |
---|---|---|---|
7D | -3.7% | -2.5% | -0.7% |
1Y | -3.1% | -13.7% | 16.7% |
Return vs Industry: PCR exceeded the Polish Chemicals industry which returned -12.8% over the past year.
Return vs Market: PCR underperformed the Polish Market which returned 16% over the past year.
Price Volatility
PCR volatility | |
---|---|
PCR Average Weekly Movement | 2.1% |
Chemicals Industry Average Movement | 4.5% |
Market Average Movement | 5.1% |
10% most volatile stocks in PL Market | 9.3% |
10% least volatile stocks in PL Market | 3.4% |
Stable Share Price: PCR has not had significant price volatility in the past 3 months.
Volatility Over Time: PCR's weekly volatility (2%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1993 | 1,440 | Wieslaw Klimkowski | www.pcc.rokita.pl |
PCC Rokita SA designs, produces, and sells chemical products in Poland and internationally. It offers chlorine and alkali; polyurethane insulation systems; household chemicals and cleaning agents; washing preparations; liquid chemicals and disinfectants; vegan body and hair cleansing products; shower gels, hair shampoos, and liquid soaps; foams; and organic products, as well as polyols, naphthalene, and phosphorus derivatives. The company also provides specialty products, including anionic surfactants, alkoxylated fatty alcohols, non-ionic surfactants, synthetic and foam-forming extinguishing agents, synthetic base oils and additives, polyester polyols, chemical raw materials, polyurethane adhesives and prepolymers, polymeric polyols, and polyether polyols.
PCC Rokita SA Fundamentals Summary
PCR fundamental statistics | |
---|---|
Market cap | zł1.70b |
Earnings (TTM) | zł158.25m |
Revenue (TTM) | zł2.05b |
10.8x
P/E Ratio0.8x
P/S RatioIs PCR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
PCR income statement (TTM) | |
---|---|
Revenue | zł2.05b |
Cost of Revenue | zł1.61b |
Gross Profit | zł435.25m |
Other Expenses | zł277.00m |
Earnings | zł158.25m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 14, 2024
Earnings per share (EPS) | 7.97 |
Gross Margin | 21.25% |
Net Profit Margin | 7.73% |
Debt/Equity Ratio | 47.0% |
How did PCR perform over the long term?
See historical performance and comparison